Note that some links may require subscriptions.
The Drug Enforcement Administration has moved to allow more healthcare providers to prescribe treatment for opioid addiction. (Reuters)
The Trump administration’s new work requirements for low-income people on Medicaid could lead to more states adopting Medicaid expansion. (AP)
Sighs of relief after Congress funds the CHIP program. (NPR)
Procedural vote Tuesday clears the way for Alex Azar’s final confirmation as Health and Human Services Secretary. (The Hill)
A Dutch nonprofit foundation has provided what it says is the first independent analysis of what pharmaceutical companies are doing to battle the problem of antibiotic drug resistance.
Novartis says a phase III study of erenumab in migraine met its primary endpoint.
What rheumatologists need to tell their patients about sleep and its effect on RA. (The Rheumatologist)
An expert discusses how generic prices are changing and whether biosimilars will cut prices. (Managed Healthcare Executive)
A new form of statin resistance? Other lipid-lowering therapies are gaining popularity despite weak evidence. (Cardiovascular Business)
NIH announces program aimed at developing tools to make gene editing safe for patients.
“With over 4 million American women giving birth annually, this is not a statistical aberration, it is a medical catastrophe.” With those words about a climbing maternal mortality rate, an ob/gyn website announces a year-long focus on the issue. (Contemporary OB/GYN)
A look at transcranial nerve stimulation for treating PTSD and major depressive disorder. (MD Magazine)
A new subspecialty, supportive oncodermatology, is emerging. (Oncology Practice)
Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: MPT_editorial@everydayhealthinc.com.